Shigeki Sugii
Agency for Science, Technology and Research · 75 works · 4,052 citations · h-index 30
Top works
- CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance
- Role of Niemann-Pick Type C1 Protein in Intracellular Trafficking of Low Density Lipoprotein-derived Cholesterol
- CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance
- PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
- Niemann-Pick Type C Disease and Intracellular Cholesterol Trafficking
- Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells
- Adipocyte Ceramides Regulate Subcutaneous Adipose Browning, Inflammation, and Metabolism
- A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann-Pick type C1 mouse brain
- Thyroid hormone (T3) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy
- Identification of Specific Cell-Surface Markers of Adipose-Derived Stem Cells from Subcutaneous and Visceral Fat Depots
- Distinct Endosomal Compartments in Early Trafficking of Low Density Lipoprotein-derived Cholesterol
- Adipose-derived stem cells: Fatty potentials for therapy
- Feeder-dependent and feeder-independent iPS cell derivation from human and mouse adipose stem cells
- Epigenetic codes of PPARγ in metabolic disease
- Trafficking defects in endogenously synthesized cholesterol in fibroblasts, macrophages, hepatocytes, and glial cells from Niemann-Pick type C1 mice
- Biotinylated θ-toxin derivative as a probe to examine intracellular cholesterol-rich domains in normal and Niemann-Pick type C1 cells
- A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes
- The current landscape of adipose-derived stem cells in clinical applications
- Adipose Tissue: Understanding the Heterogeneity of Stem Cells for Regenerative Medicine
- Uncertain Oversight of Regenerative Medicines in Japan under the ASRM